biote Corp. (NASDAQ:BTMD) Major Shareholder Guines Llc Acquires 7,321 Shares

biote Corp. (NASDAQ:BTMD) major shareholder Guines Llc acquired 7,321 shares of the company’s stock in a transaction that occurred on Thursday, April 3rd. The shares were acquired at an average cost of $3.24 per share, with a total value of $23,720.04. Following the purchase, the insider now owns 4,040,868 shares in the company, valued at $13,092,412.32. This represents a 0.18 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Guines Llc also recently made the following trade(s):

• On Monday, April 7th, Guines Llc bought 43,378 shares of biote stock. The shares were bought at an average price of $3.15 per share, for a total transaction of $136,640.70.
• On Monday, March 31st, Guines Llc purchased 106,000 shares of biote stock. The stock was bought at an average cost of $3.32 per share, with a total value of $351,920.00.
• On Monday, March 17th, Guines Llc acquired 100 shares of biote stock. The shares were bought at an average cost of $3.74 per share, for a total transaction of $374.00.
• On Thursday, March 13th, Guines Llc bought 750,000 shares of biote stock. The stock was bought at an average cost of $3.22 per share, with a total value of $2,415,000.00.

biote Stock Performance

Shares of NASDAQ BTMD traded down $0.04 during midday trading on Monday, reaching $3.25. 218,865 shares of the stock were exchanged, compared to its average volume of 184,100. The stock has a market capitalization of $177.81 million, a P/E ratio of 12.50 and a beta of 1.17. The company has a 50 day simple moving average of $4.35 and a 200 day simple moving average of $5.30. biote Corp. has a twelve month low of $3.04 and a twelve month high of $8.44.

Institutional Investors Weigh In On biote

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD acquired a new position in shares of biote in the 4th quarter valued at $67,000. Commonwealth Equity Services LLC purchased a new stake in biote in the 4th quarter valued at about $68,000. Public Employees Retirement System of Ohio acquired a new position in biote in the fourth quarter valued at about $69,000. Intech Investment Management LLC acquired a new position in shares of biote in the 4th quarter worth approximately $71,000. Finally, SG Americas Securities LLC acquired a new position in biote during the fourth quarter worth $76,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Craig Hallum lowered their price target on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.